Site Search

1. 221.
   AMP/assets/File/position-statements/2017/AMP-CAPCommentsMGMT_DL37001_000.pdf?pass=...

   In this study, 91% of patients whose original biopsies demonstrated methylated MGMT had pseudo-progression (versus 41% of patients without methylated MGMT, P = .0002), and were best managed by continuing the current therapy. The retrospective determination of MGMT promoter methylation status in the pre-treated, original biopsies can be critical in the

   https://www.amp.org/AMP/assets/File/position-statements/2017/AMP-CAPCommentsMGMT...
2. 222.
   PowerPoint Presentation

   with as little as 20% cancer cells.Strong Recommendation: Laboratories should not use total EGFR expression by IHC testing to select ... targeted kinase inhibitors should deploy assays capable of detecting EGFRT790M mutations in as little as 5% of viable cells.No Recommendation: There is currently insufficient evidence to support a recommendation for or

   https://www.amp.org/AMP/assets/File/clinical-practice/CAP-IASLC-AMP_Lung_Molec_T...
3. 223.
   Microsoft Word - TechAward_Winners'_Abstracts.doc

   BRAF mutations were identified in 32 thyroid FNA samples. In 30/32 (94%) cases, a common BRAF V600E mutation was detected. In addition, two rare types of BRAF ... the three assays performed very well from whole blood using BloodDirect PCR buffers, giving a 100 % concordance with robust results as from extracted DNA. We found this buffer to be compatible with

   https://www.amp.org/AMP/assets/File/awards/technologist/2008TechAward_Winners'_A...
4. 224.
   Genomic Sequencing Procedure Cost and Value Models - Association for Molecular...

   The JMD paper, which summarizes the results of this project is available here: http://jmd.amjpathol.org/article/S1525-1578%2816%2900053-2/fulltext The models are available at no charge. Upon download, you will be asked to fill out your contact information and agree to the terms and conditions of use. All models will then be downloaded in a zip file. The

   https://www.amp.org/advocacy/advocacy-resources/coverage-and-reimbursement/ngs-p...
5. 225.
   Member Spotlight: Somak Roy - Association for Molecular Pathology

   I gave AMP my 100% to AMP and received a 200% boost to my career. Get involved in AMP and dance to the “AMP song” at the “Amazing Molecular Party” at the Annual Meeting. It summarizes what AMP can do for you! Corporate Partners Diamond Partner Diamond Partner Platinum Partner Gold Partner Gold Partner Gold Partner Gold Partner Gold Partner Gold

   https://www.amp.org/membership/member-spotlights/member-spotlight-somak-roy/
6. 226.
   Clinical Practice Guidelines and Comments

   Advisor status to AMA CPT; this would require at least 50% of physician members of AMP to also be members of AMA. 2. Coverage ... satisfaction with the quality of the presentation format. Date Topic Speaker Attendance (Registered) Attentiveness (%) Evaluation -(Education/Content/Quality) 2/23/2010 Microsatellite instability testing in colon cancer Antonia

   https://www.amp.org/AMP/assets/File/committees/reports/CompiledReports2010.pdf?p...
7. 227.
   C:\Users\MWILLI~1\AppData\Local\Temp\mso68A7.tmp

   Over ten years, my rough calculation shows that, conservatively, at least 20% of us have served on one committee or another. That’s a fantastic rate of service. ... the effort you invest. Our membership has grown by an average annual rate of nearly 17%. That’s impressive. Clearly, AMP is the place to be for molecular diagnostics. Our many generous

   https://www.amp.org/AMP/assets/File/newsletter/AMP-NL_2004_10th_Anniv_FINAL.pdf?...
8. 228.
   2025 Annual Meeting Corporate Workshops - Association for Molecular Pathology

   We present new data on multiplex digital PCR assays designed for circulating tumor DNA, enabling detection down to 0.1% variant allele frequency. Targets include ESR1, BRAF, PIK3CA, EGFR, and KRAS, ... PCR assays designed for circulating tumor DNA, enabling detection down to 0.1% variant allele frequency. Targets include ESR1, BRAF, PIK3CA, EGFR, and KRAS, key

   https://www.amp.org/education/corporate-workshops/2025-annual-meeting-corporate-...
9. 229.
   AMP/assets/File/position-statements/2015/AMPresponsetoECRFIfinal.pdf?pass=91

   cancer occur less than 1% of the time. For example, while lung adenocarcinomas have a rather high incidence, some targetable ... Medical Device Innovation: Barriers to Market for Molecular Diagnostic Tests. http://www.amp.org/Position%20Statements/AMPComments_FDAMedicalDeviceWorkshop_062410_final.pdf iv FDA Webinar: Framework for Regulatory Oversight of LDTs

   https://www.amp.org/AMP/assets/File/position-statements/2015/AMPresponsetoECRFIf...
10. 230.
    AMP/assets/File/advocacy/AMP-Comments-on-FDA-Draft-Guidance-Validation-of-Certain-...

    August 2020, AMP found that over 80% of ASSOCIATION FOR MOLECULAR PATHOLOGY Providing global expertise in molecular testing that drives patient care 6120 Executive Boulevard, Suite 700, Rockville, Maryland, 20852 Tel: 301-634-7987 | Fax: 301-634-7995 | amp@amp.org | www.amp.org laboratories surveyed reported experiencing supply chain interruptions that

    https://www.amp.org/AMP/assets/File/advocacy/AMP-Comments-on-FDA-Draft-Guidance-...